PMID- 15887013
OWN - NLM
STAT- MEDLINE
DCOM- 20060623
LR  - 20240427
IS  - 0340-7004 (Print)
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Linking)
VI  - 55
IP  - 3
DP  - 2006 Mar
TI  - Chaperone-rich cell lysates, immune activation and tumor vaccination.
PG  - 329-38
AB  - We have utilized a free-solution-isoelectric focusing technique (FS-IEF) to 
      obtain chaperone-rich cell lysates (CRCL) fractions from clarified tumor 
      homogenates. The FS-IEF technique for enriching multiple chaperones from tumor 
      lysate is relatively easy and rapid, yielding sufficient immunogenic material for 
      clinical use. We have shown that tumor-derived CRCL carry antigenic peptides. 
      Dendritic cells (DCs) uptake CRCL and cross-present the chaperoned peptides to T 
      cells. Tumor-derived CRCL induce protective immune responses against a diverse 
      range of murine tumor types in different genetic backgrounds. When compared to 
      purified heat shock protein 70 (HSP70), single antigenic peptide or 
      unfractionated lysate, CRCL have superior ability to activate/mature DCs and are 
      able to induce potent, long lasting and tumor specific T-cell-mediated immunity. 
      While CRCL vaccines were effective as stand-alone therapies, the enhanced 
      immunogenicity arising from CRCL-pulsed DC as a vaccine indicates that CRCL could 
      be the antigen source of choice for DC-based anti-cancer immunotherapies. The 
      nature of CRCL's enhanced immunogenicity may lie in the broader antigenic peptide 
      repertoire as well as the superior immune activation capacity of CRCL. Exongenous 
      CRCL also supply danger signals in the context of apoptotic tumor cells and 
      enhance the immunogenicity of apoptotic tumor cells, leading to tumor-specific T 
      cell dependent long-term immunity. Moreover, CRCL based vaccines can be 
      effectively combined with chemotherapy to treat cancer. Our findings indicate 
      that CRCL have prominent adjuvant effects and are effective sources of tumor 
      antigens for pulsing DCs. Tumor-derived CRCL are promising anti-cancer vaccines 
      that warrant clinical research and development.
FAU - Zeng, Yi
AU  - Zeng Y
AD  - Department of Pediatrics, Steele Memorial Children's Research Center, University 
      of Arizona, 1501 N. Campbell Ave., PO Box 245073, Tucson, AZ 85724-5073, USA.
FAU - Graner, Michael W
AU  - Graner MW
FAU - Katsanis, Emmanuel
AU  - Katsanis E
LA  - eng
GR  - R01 CA104926/CA/NCI NIH HHS/United States
GR  - R21 CA102410/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20050511
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Heat-Shock Proteins)
SB  - IM
MH  - Animals
MH  - Antigen Presentation/immunology
MH  - Antigens, Neoplasm/*immunology
MH  - Cancer Vaccines/*immunology
MH  - Dendritic Cells/immunology
MH  - Heat-Shock Proteins/*immunology
MH  - Humans
MH  - Lymphocyte Activation/*immunology
MH  - Neoplasms/immunology
PMC - PMC11030847
EDAT- 2005/05/12 09:00
MHDA- 2006/06/24 09:00
PMCR- 2005/05/11
CRDT- 2005/05/12 09:00
PHST- 2004/10/29 00:00 [received]
PHST- 2005/02/21 00:00 [accepted]
PHST- 2005/05/12 09:00 [pubmed]
PHST- 2006/06/24 09:00 [medline]
PHST- 2005/05/12 09:00 [entrez]
PHST- 2005/05/11 00:00 [pmc-release]
AID - 694 [pii]
AID - 10.1007/s00262-005-0694-1 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2006 Mar;55(3):329-38. doi: 10.1007/s00262-005-0694-1. 
      Epub 2005 May 11.